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ABSTRACT  
Objective: The purpose of this work was to enhance oral bioavailability of Bromocryptine Mesylate by preparing SMEDDS (self-micro emulsifying 
drug delivery system) 
Methods: Screening of oils, surfactants and co-surfactants were done by solubility study & pseudo ternary diagram. The batches of Bromocryptine 
Mesylate (BM)–SMEDDS were prepared and evaluated for droplet size analysis, poly dispensability index (PDI), robustness to dilution, zeta 
potential, in vitro dissolution. The optimized batch was compared with commercially available quick release tablets of BM (Brainstar®, 0.8 
mg/tablet) by in vivo study (Pharmacodynamic study in rats). 
Results: Based on the drug’s solubility study, Akoline MCM, Tween80 and PEG400 were selected as oil, surfactant and co-surfactant, respectively. 
By pseudo ternary diagram, the components’ ratios were screened. In vitro drug release of the optimized batch was lower than the commercial 
preparation but in in vivo study, optimized batch was similar with commercial tablets. 
Conclusion: From the study, it was concluded that the group treated with optimized BM-SMEDDS showed better and sustained reduction in blood 
sugar as compared to control group and the group treated with marketed formulation, indicated improvement in bioavailability of drug.  
Keywords: Bromocryptine Mesylate, Type–II Diabetes, Self micro emulsifying drug delivery system, Bioavailability, Pharmacodynamic study 
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INTRODUCTION 
Oral intake has been the most sought-after route of drug delivery by 
both patients and drug manufacturers for the treatment of most 
pathological states. Despite tremendous strides made in novel non-
oral drug delivery systems, the majority of the drugs available 
commercially are oral formulations. Nevertheless, with oral delivery, 
over half of the drug compounds are diminished in the 
gastrointestinal tract because of their high lipophilicity and 
consequently poor aqueous solubility [1]. Oral bioavailability of such 
drugs, being primarily a function of their solubility and dissolution, 
[2] tends to exhibit inadequate magnitude with high intra-and inter-
subject variability. Further, oral bioavailability also depends on upon 
a multitude of other drug factors such as stability in GI fluids, 
intestinal permeability, resistance to metabolism by cytochrome 
P450 family of enzymes present in gut enterocyte and liver 
hepatocytes and interactions with efflux transporter systems such as 
P-glycoprotein (P-gp) [3,4]. 
Type-II diabetes is a growing global pandemic that is estimated to af flict 
approximately 350 million people by the year 2030 [5]. This growing 
threat to human health requires medical interventions to lessen the 
morbidity associated with type-II diabetes. Type-II Diabetes is 
characterized by elevated fasting and postprandial plasma glucose 
concentrations which result from increased endogenous glucose 
production (EGP), decreased insulin-mediated muscle glucose disposal 
and suppression of endogenous glucose release and inadequate 
pancreatic insulin secretion. Obesity is a well-established risk factor for 
type-II diabetes. Extensive experimental evidence indicates that 
circadian neuroendocrine rhythms play a pivotal role in the 
development of seasonal changes in body fat stores and insulin 
sensitivity. Specifically, temporal changes in the interaction of 2 distinct 
neural circadian oscillations, mediated by dopaminergic and 
serotonergic neurotransmitter activity, have been shown to regulate the 
dramatic seasonal alterations in body weight and body composition that 
are characteristic of all vertebrate classes from teleost to mammals. Data 
obtained in rats, pigs, and humans suggest that similar mechanisms may 
play a role in the development of non-seasonal obesity and insulin 
resistance [6]. 
Bromocriptine mesylate (BM), an ergot derivative, is a sympatholytic 
dopamine D2 receptor agonist that exerts inhibitory effects on 
serotonin turnover in the central nervous system. It has been 
proposed that bromocriptine can reverse many of the metabolic 
alterations associated with obesity by resetting central (hypothalamic) 
circadian organization of monoamine neuronal activities. BM 
approved by USFDA for treatment Type-II Diabetes (Dec. 2008) is 
practically insoluble in water [7] and shows pH dependent solubility 
[8]. Only about 30% of an oral dose is absorbed from GIT 
bioavailability is only about 6% owing to extensive first-pass 
metabolism. Bromocriptine improves glycemic control and glucose 
tolerance in obese type-II diabetic patients. Both reductions in fasting 
and postprandial plasma glucose levels appear to contribute to the 
improvement in glucose tolerance. The bromocriptine induced 
improvement in glycemic control is associated with enhanced 
maximally stimulated insulin-mediated glucose disposal [6]. 
Self micro emulsifying drug delivery systems (SMEDDS)-isotropic 
mixtures of the drug, lipids (natural or synthetic oils), and 
emulsifiers (solid or liquid), usually with one or more hydrophilic 
co-solvents/co-emulsifiers are relatively newer, lipid-based 
technological innovations with immense promise in enhancing the 
oral bioavailability of drugs. [9, 10] These formulations have been 
shown to overcome the slow and incomplete dissolution of a drug, 
facilitate the formation of its solubilized phase, increase the extent of 
its transportation via the intestinal lymphatic system and bypass the 
P-gp efflux, thereby augmenting drug absorption from the GI tract 
[11]. This presents the opportunity to prepare the formulation in 
SMEDDS form to enhance dissolution with the bioavailability of 
poorly water soluble drug-BM for better treatment of diabetes.  
MATERIALS AND METHODS 
Materials 
Bromocriptine Mesylate (Helios Pharmaceuticals, Baddi, India), 
Etocas 35 HV-LQ (Croda Europe Ltd., Snaith Goole, United Kingdom), 
Tween 80 (Hi-Media, Vadodara, India), Captex 500 (Abitec 
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Corporation, Columbus, USA), Capmul MCM C8 (Abitec Corporation, 
Columbus, USA), Methanol (Loba Chemie Pvt. Ltd., Mumbai, India), 
Akoline MCM (Aarhus Karlshamn Sweden AB), PEG 400 (Loba 
Chemie Pvt. Ltd., Mumbai, India), Potassium Chloride (Merck 
Specialities Pvt. Ltd., Bengaluru, India), Hydrochloric acid (Merck 
Specialities Pvt. Ltd.), Crodamol GTCC (Croda Europe Ltd., Snaith 
Goole, United Kingdom) were used. All other reagents and solvents 
were of analytical grades. 
Screening of oil, surfactants and co-surfactants (solubility study 
of BM in various oil, surfactants and co-surfactants)  
The most important criterion for the screening of components for 
SMEDDS is the solubility of the poorly soluble drug in oils, 
surfactants, and co-surfactants. 10 mg of BM was added in each tube 
containing either oil surfactant or co-surfactant mixed using 
cyclomixer. After visual assessment of solubility of the drug, the 
additional drug infraction of 10 mg was subsequently added in each 
tube to determine the maximum solubility of drug in the particular 
solvent. The tightly closed tubes were shaken for 48 h at 50 strokes 
per minute in an isothermal shaker. The procedure was continued 
till highest solubility observed [12]. 
Construction of pseudo-ternary phase diagram 
The existence of microemulsion regions was determined by using 
pseudo ternary phase diagram. SMEDDS were diluted under 
agitation condition using water titration method. The mixture of oil 
and surfactant/co-surfactant mixture (Smix) at certain weight ratios 
were diluted with water in a dropwise manner. The ratios of 
surfactant/co-surfactant were prepared in the specific manner, i.e., 
1:1, 1:2 and 2:1 (%w/w). Each of these ratios was mixed with 
increasing percentage of oil, i.e., 10%, 20%, 30%, 40% up to 90% of 
oil to get phase diagram. Then, each mixture was titrated with water, 
and agitation was provided by a magnetic stirrer.  The formation of 
microemulsion regions was monitored visually for turbidity–
transparency–turbidity. These values of oil, surfactant and 
cosurfactant were used to determine the boundaries of 
microemulsion region in the pseudo-ternary phase diagram. After 
the identification of microemulsion region in the phase diagrams, 
the microemulsion formulations were selected at desired 
component ratios. [12] 
Preparation of SMEDDS 
A series of microemulsions of SMEDDS were prepared with varying 
ratios of oil, surfactant, and cosurfactant as mentioned in table 1. 
Formulations A, B, and C were prepared using Akoline MCM as oil, 
Tween 80 as a surfactant, and PEG 400 as co-surfactant. In all the 
formulations, the level of BM was kept constant to 7.5% w/w of 
SMEDDS. Briefly, oil, surfactant, and cosurfactant were accurately 
weighed into glass vials according to their ratios. The amount 
SMEDDS should be such that it solubilizes the drug (single dose) 
completely. Hence, 0.8 mg of BM was dissolved in 0.125 g of 
SMEDDS. Then, the components were mixed by gentle stirring and 
vortex mixing at 25˚C until clear oily phase was obtained. The 
formulation was equilibrated at ambient temperature for at least 48 
h and examined for signs of turbidity or phase separation prior to 
self-emulsification and particle size studies [12]. 
 
Table 1: Three composition of SMEDDS (containing 7.5 mg BM 
% w/w) 
Vehicle (%w/w) A B C 
BM 7.5 7.5 7.5 
Akoline MCM (Oil) 4.5 9.0 13.5 
Tween 80 (Surfactant) 70.9 67.2 63.4 
PEG 400 (Cosurfactant) 34.1 32.4 30.5 
 
Characterization of SMEDDS 
Dispersibility test  
Self-emulsification efficiency of the prepared formulation was 
assessed using a standard USP XXII dissolution apparatus. 0.5 ml of 
each formulation was added to 500 ml of distilled water at 
37±1.0 °C. A standard stainless steel dissolution paddle rotating 
at 50 rpm was used to provide gentle agitation. Emulsification 
time was assessed visually and In vitro performance of the 
formulations was visually assessed using the following grading 
system [1]. 
Robustness to dilution  
0.5 ml of SMEDDS was mixed with 500 ml of 0.1 N HCl. The diluted 
microemulsions were stored for 12 h at room temperature and 
observed for any signs of phase separation or drug precipitation [1]. 
Droplet sizes analysis  
Microemulsion globule size was determined using a photon 
correlation spectrometer (Malvern Zetasizer Nano S90, Malvern 
Instruments, Worcestershire, UK) based on the laser light scattering 
phenomenon which analyzes the fluctuations in light scattering. 
Light scattering was monitored at 25 °C at a 90 ° angle. Properly 
diluted samples of microemulsion (0.1 ml) were dispersed in 50 ml 
of buffer pH 1.2 and were taken for droplet size analysis. Average 
droplet size was determined [1]. 
Zeta potential determination 
Zeta potential was measured by photon correlation spectroscopy 
using zeta sizer (Malvern Zetasizer Nano ZS, UK; Malvern 
Instruments, Worcestershire, UK), which measures the potential 
range from −120 to 120 V. Zeta potential results of all  SMEDDS 
formulations taken after diluted 20 times with buffer pH 1.2 [1, 13]. 
In vitro dissolution study  
BM SMEDDS formulation was filled in size ‘3’ hard gelatin capsules. 
In vitro release profiles of SMEDDS of BM was studied using USP 
XXIII apparatus type I (Electrolab India, Mumbai, India) at 37±0.5 °C 
and 120 rpm in 0.1N hydrochloric acid as the dissolution media (500 
ml) and an aliquot (5 ml) of sample was collected at predefined time 
intervals (0, 5, 15, 30, 45 and 60 min) from the dissolution medium 
and replaced with fresh media. The amount of BM released in the 
dissolution medium was determined by fluorescence spectrometer 
(Perkin Elmer LS55, USA) at λExcitation 315 nm and λEmission 425 nm. 
The results were analyzed for statistical significance by student’s t-
test using Graph pad Prism software. All data were expressed as 
mean±S. E (P<0.05). Group means were considered to be 
significantly different at P<0.05 [13]. 
In vivo study  
Wistar rats with weighing>200g were utilized for this in vivo study. 
Animals were housed in an air-conditioned animal room at 25±1 °C 
and 55% relative humidity with a 12 h light/dark cycle and 
maintained with free access to water and food Italic. The 
experimental protocol was approved by institutional animal ethics 
committee vide (Protocol No RPCP/IAEC/2011-2012/MPH-PT-06). 
All experiments were conducted as per the norms of the committee 
for the purpose of control and supervision of experiments on 
animals (CPCSEA). Diabetes was induced by a single intraperitoneal 
injection of streptozotocin (STZ) (60 mg/kg) [14] (Sigma, St. Louis, 
MO, USA) freshly dissolved in a 0.1 M citrate buffer (pH 4.3). After 2 
d, rats with blood glucose levels ≥300 mg/dL  were selected for the 
study [15, 16]. (STZ produces DNA damage to pancreatic icelet cells 
which leads to hyperglycemic state and blood glucose level 
increased to>300 mg/dl. so animals showed hyperglycaemia.) 
The rats were assigned to three different groups-5 rats each and 
treated as follows:  
Group I: Diabetic Control, no drug treatment (given only distilled 
water) 
Group II: Diabetic treated with BM SMEDDS (0.8 mg/kg) (dispersed 
outside and equivalent dose administered). 
Group III: Diabetic treated with marketed formulation, 0.8 mg/kg of 
Brainstar tablet, USV Limited, India. (Tablet disintegrated outside 
and equivalent dose administered) 
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The above-mentioned doses were administered once a day up to 28th 
day of study. Blood was collected from the tail vein on day 0, 7, 14, 
21 and 28. Blood glucose level was determined using glucometer 
(Johnson and Johnson) based on the glucose oxidase/peroxidase 
method. The results were analyzed for statistical significance by 
two-way analysis of variance (ANOVA) test using Graph pad prism 
software. All data were expressed as mean±SD (P<0.05). Group 
means were considered to be significantly different at P<0.05. 
RESULTS AND DISCUSSION 
Solubility study 
The solubility of BM was checked in a number of solvents and 
presented in a graphical manner in fig. 1. Based on the solubility 
data, Akoline MCM was selected as oil phase, Tween 80 as surfactant 
and PEG 400 as co-surfactant since these solvents showed better 
solubility.  
Pseudo ternary phase diagram 
To determine the optimum concentration of oil, surfactant, and 
cosurfactant, phase diagrams were constructed. SMEDDS forms 
microemulsion when titrated with water under agitation condition. 
The particle size of the microemulsion is less than 100 nm and as the 
energy required to form microemulsion is very low, it is a 
thermodynamically spontaneous process. 
This process is facilitated by the presence of a surfactant. The 
surfactant forms a layer around oil globule in such a way that polar 
head lies toward aqueous and nonpolar tail pull out oil and thereby 
reduces surface tension between oil phase and an aqueous phase. 
Another factor affecting the formation of the microemulsion is the 
ratio of surfactant and co-surfactant. The lipid mixtures with a 
different surfactant, co-surfactant, and oil ratios lead to the 
formation of SMEDDS with different properties. Since surfactant and 
co-surfactant adsorb at the interface and providing a mechanical 
barrier to coalescence, selection of oil, surfactant, and cosurfactant 




Fig. 1: Graph showing solubility of BM in different various oils, 
surfactants and co-surfactants 
 
Three different formulations were prepared using different oils, 
surfactants, and cosurfactants in varying ratios. SMEDDS were 
formulated using same excipients with three different S/CoS ratios 
of 2:1, 1:1, and 1:2 and diluted to get microemulsion region as 
mentioned in fig.2. Microemulsion regions were observed visually. 
Initially, the concentration of oil taken was. 
  
Table 2: Percentage of water required for microemulsion formation 



















1:9 7 64 29 4 34 62 - - - 
2:8 16 64 20 15 62 23 7 27 66 
3:7 31 46 23 22 51 26 18 42 39 
4:6 36 36 29 29 43 29 25 38 38 
5:5 44 30 26 38 38 23 31 31 38 
6:4 52 22 26 44 30 26 40 27 33 
7:3 59 15 26 50 21 29 42 18 39 
8:2 67 7 26 60 15 25 55 14 31 
9:1 1 28 71 64 7 29 56 6 38 
 
Table 3: Visual assessment of SMEDDS 
Grade Dispersibility and appearances Time of self-micro emulsification 
A 
 
Rapid forming microemulsion which is clear or 




Rapid forming, slightly less clear emulsion, 
which has a bluish white appearance 
<1 min 
C Bright white emulsion (similar to milk) <2 min 
D Dull, grayish white emulsion with a slightly oily appearance that is slow to emulsify >3 min 
E Exhibit poor or minimal emulsification with 
large oil droplets present on the surface 
>3 min 
 
Table 4: Result of dispersibility of SMEDDS in distilled water 
Batch No Appearance  Emulsification Time  Grade 
SM1 Clear, Slight bluish <1 min A 
SM2 Clear, Slight bluish <1 min A 
SM3 Less Clear, bluish white <1 min B 
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Fig. 2: Phase diagram prepared with the following components: 
oil-Akoline MCM, surfactant-Tween 80, and co-surfactant-PEG 
400. S/CoS ratio of 1:2, 1:1 and 2:1 
 
Maximum, i.e., 90%, and the amount of S/CoS was kept to a 
minimum, i.e., 10% as per the table 3. Gradually, oil concentration 
was decreased, and that of S/CoS was increased. It was observed 
during these experiments that high concentration of oil forms a poor 
emulsion with entrapment of very less amount of water upon 
dilution. Another observation was that as the concentration of S/CoS 
increases, the time estimated to form micro emulsion decreases.  
A series of micro emulsions were prepared at different 
concentrations of oil and S/CoS, but the concentration of oil was 
found to be a rate-limiting factor, and in all cases, high oil 
concentration resulted in poor emulsion region. Hence, it was 
decided to keep the oil concentration less than 10%. Ternary phase 
diagram of 2:1 w/w S: CoS resulted in higher micro emulsion region 
as compared to other, so it was selected for formulation 
development trials. 
Dispersibility test 
Dispersibility of all the batches was recorded in terms of appearance and 
self-emulsification time, and all the results were recorded as per table 3. 
All the formulations have shown good dispersibility in distilled water as 
a dispersibility medium. Self-emulsification time for all the batches found 
within 60 seconds as mentioned in table 4. Rapid self-emulsion time was 
indicated that in GI fluid these formulations rapidly form dispersion with 
small droplet size. All the formulations have shown good dispersibility in 
distilled water as a dispersibility medium. 
Robustness to dilution 
Diluted SMEDDS did not show any precipitation or phase separation 
on storage in various dilution media. This reveals that all media 
were robust to dilution. 
Droplet sizes analysis 
There is a relationship between the droplet size and the 
concentration of the surfactant being used. As per the earlier 
research, increasing the surfactant concentration could lead to 
droplets with smaller mean droplet size. This could be explained by 
the stabilization of the oil droplets as a result of the localization of 
the surfactant molecules at the oil-water interface. On the other 
hand, As per Literature, the mean droplet size may increase with 
increasing surfactant concentrations. This phenomenon could be 
attributed to the interfacial disruption elicited by enhanced water 
penetration into the oil droplets mediated by the increased 
surfactant concentration and leading to the ejection of oil droplets 
into the aqueous phase [17].  
The particle size determination following self-microemulsification is 
a critical factor to evaluate a self-microemulsion system as droplet 
size is reported to have an effect on drug absorption. The smaller is 
the droplet size; the larger is the interfacial surface area provided for 
drug absorption [17]. The optimization of SMEDDS was based on the 
particle size of SMEDDS. The mean particle size and PDI for all the 
SMEDDS and optimized formulation’s globule size have been 
summarized in table 5 and fig. 3 respectively. The Results are of 
triplicate study.  
 
Table 5: Result of globule size analysis in pH 1.2 buffer 
Batch no. Globule size Poly dispersibility index 
SM1 28.53±27.33 0.30±0.07 
SM2 12.63±2.65 0.24±0.07 
SM3 140.96±57.55 0.23±0.03 
Mean of 3 measurements±SD (n = 3) 
 
 
Fig. 3: Globule size of optimized SMEDDS formulation 
 
Poly dispersity is the ratio of standard deviation to the mean 
droplet size. This signifies the uniformity of droplet size within 
the formulation. The higher the value of poly dispersity, the 
lower is the uniformity of the droplet size in the formulation. 
The poly dispersity values of SMEDDS SM1, SM2, and SM3 are 
0.3±0.07, 0.24±0.07, and 0.23±0.03, respectively, which indicates 
uniformity of droplet size within the formulation. SMEDDS with 
increased globule size causes agglomeration of globules and 
suffers with the instability of the system. SMEDDS SM1 and SM2 
were found having a particle size less than 100 nm which fulfil  
the criteria of the microemulsion and low PDI shows the 
uniformity of particles. But SMEDDS SM2 having least particle 
size, Therefore, SMEDDS SM2 was optimized and considered for 
further in vitro and in vivo studies. 
Zeta potential determination 
The Zeta potential of the optimized batch (SM2) was found to be 
14.7 mV shown in fig. 4. Barry  
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Fig. 4: Zeta potential of optimized SMEDDS formulation 
 
and Eggenton has shown that the intestinal cell interior negatively 
charged relative to mucosal fluid [18]. The positively charged oil 
droplets formed by SMEDDS could produce strong interaction with 
the mucosal surface, improve the adhesion of the positively charged 
droplets to the intestinal mucosa, and increase drug uptake from the 
mucosa, further improving the oral bioavailability [13].  
In vitro dissolution study 
The in vitro dissolution profile of optimized SMEDDS formulation 
(SM 2) and Brainstar® tablet (marketed formulation) was studied in 
0.1N hydrochloric acid. It was observed that optimized SMEDDS 
formulation SM2 and Brainstar® release more than 85% of 
Bromocriptine Mesyalte within 15 min. Optimized SMEDDS 
formulation and Brainstar® tablet showed similar dissolution 
profile in 0.1 N Hydrochloric acid. The comparative dissolution 
profile of optimized SMEDDS formulation and Brainstar® tablet 
have been summarized in fig.5. The dissolution profile of optimized 
batch was compared with marketed formulation of BM tablet 
(BrainStar®) and no significant difference between both release 
profiles was found (P<0.05). 
 
 
Fig. 5: Comparative dissolution profile of optimized SMEDDS 
formulation and Brainstar® tablet (Marketed formulation) 
Mean of 3 measurements±SD (n = 3) 
 
In vivo study 
In present study, STZ treated diabetic control animals showed 
significant increase in blood glucose level from zero to four weeks 
(study period) during the experiment while a significant reduction was 
observed in blood glucose level during study period in optimized BM 
SMEDDS treated diabetic animals as compared to marketed 
formulation of BM treated diabetic animals mentioned fig. 6. 
 
 
Fig. 6: Result of blood glucose level of rats treated with Bromocriptine SMEDDS and marketed formulation. Values are statistically 
significant at ** p<0.01 and **** p<0.0001 as compared with diabetic control: $ p<0.05 as compared with the group treated marketed 
formulation. Mean of 3 measurements±SD (n = 3) 
 
The amount of BM released from SMEDDS formulation, SM2 was 
96.50±1.07 % in 60 min comparatively lower than the marketed 
formulation-Brainstar® (98.36±1.08) shown in fig. 5. But in, in vivo 
study, SMEDDS formulation, SM2 showed a better result than 
marketed formulation-Brainstar®. This might be because of small 
globule size and the higher surface area in case of SMEDDS, which 
permitted faster rate of drug release. The reason behind this might 
be the use of surfactant-Tween 80 and Cosurfactant–PEG 400 which 
are good solubilizers, and they enhanced the permeability of the 
pure drug in, in vivo.  
CONCLUSION 
SMEDDS of BM was prepared and optimized by using in vitro 
parameters like particle size and poly dispersity index. Optimized 
SMEDDS contains Akoline MCM as the oil phase, Tween 80 as a 
surfactant and PEG 400 as co-surfactant. This optimized SMEDDS 
showed similar in vitro release as compared with the marketed 
formulation. In vivo pharmacodynamic evaluation of optimized batch 
showed a significant increase in hypoglycemic activity as compared 
to the oral marketed formulation. The present study indicates that 
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the use of oral SMEDDS delivery of BM may be an option to improve 
its bioavailability. However, pharmacokinetic studies and clinical 
studies are required to perform to establish therapeutic potential of 
this system. 
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